SPG7

SPG7 matrix AAA peptidase subunit, paraplegin, the group of AAA ATPases

Basic information

Region (hg38): 16:89490718-89557766

Previous symbols: [ "CMAR" ]

Links

ENSG00000197912 ∙ NCBI:6687 ∙ OMIM:602783 ∙ HGNC:11237 ∙ Uniprot:Q9UQ90 ∙ AlphaFold ∙ GenCC ∙ jax ∙ Sfari ∙ GnomAD ∙ Pubmed ∙ ClinVar

Phenotypes

GenCC

Source: genCC

• hereditary spastic paraplegia 7 (Definitive), mode of inheritance: AR
• lateral sclerosis (Supportive), mode of inheritance: AD
• hereditary spastic paraplegia 7 (Supportive), mode of inheritance: AD
• hereditary spastic paraplegia 7 (Definitive), mode of inheritance: Mitochondrial
• hereditary spastic paraplegia 7 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

Condition	Inheritance	Intervention Categories	Intervention/Rationale	Manifestation Categories	References
Spastic paraplegia 7, autosomal recessive	AR	General	Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing	Neurologic	9635427; 9634528; 16534102; 18200586; 18799786; 20108356; 21623769; 22571692; 22964162
Heterozygotes may demonstrate manifestations

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SPG7 gene.

• Hereditary spastic paraplegia 7 (595 variants)
• not provided (372 variants)
• not specified (94 variants)
• Hereditary spastic paraplegia (72 variants)
• Inborn genetic diseases (44 variants)
• SPG7-related condition (14 variants)
• Spastic Paraplegia, Recessive (4 variants)
• Spastic ataxia (3 variants)
• Mitochondrial disease (2 variants)
• Intellectual disability (2 variants)
• Cerebral palsy (1 variants)
• Dysarthria;Spastic paraparesis;Gait ataxia;Cerebral cortical atrophy (1 variants)
• Polyneuropathy (1 variants)
• Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 (1 variants)
• KBG syndrome (1 variants)
• Distal spinal muscular atrophy (1 variants)
• Optic nerve hypoplasia (1 variants)
• Proximal spinal muscular atrophy (1 variants)
• Spastic ataxia;Sensorimotor neuropathy (1 variants)
• - (1 variants)
• Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome (1 variants)
• Sensorimotor neuropathy;Spastic ataxia (1 variants)
• Memory impairment;Seizure;Spastic paraplegia;Gait ataxia (1 variants)
• Spastic paraparesis;Dysarthria;Gait ataxia;Cerebral cortical atrophy (1 variants)
• Spastic tetraparesis (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SPG7 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type	Pathogenic	Likely pathogenic	VUS	Likely benign	Benign	Sum
synonymous			17	112	4	133
missense	6	19	280	8	3	316
nonsense	15	11	4			30
start loss		1				1
frameshift	36	6	2			44
inframe indel	1	2	5			8
splice donor/acceptor (+/-2bp)	6	12				18
splice region	2	1	20	23	2	48
non coding	1		14	136	60	211
Total	65	51	322	256	67

Highest pathogenic variant AF is 0.000402

Variants in SPG7

This is a list of pathogenic ClinVar variants found in the SPG7 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position	Type	Phenotype	Significance	ClinVar
16-89508168-G-A			Benign (Jun 19, 2018)
16-89508187-C-CA			Benign (Jun 14, 2018)
16-89508277-G-C			Benign (Jun 23, 2018)
16-89508278-G-C			Likely benign (Feb 21, 2019)
16-89508295-A-C			Likely benign (Nov 08, 2018)
16-89508418-A-G		Hereditary spastic paraplegia 7 • SPG7-related disorder	Pathogenic/Likely pathogenic (Oct 01, 2023)
16-89508419-T-A		Hereditary spastic paraplegia 7 • not specified	Conflicting classifications of pathogenicity (Nov 26, 2022)
16-89508419-T-G		Hereditary spastic paraplegia 7	Pathogenic (Nov 02, 2023)
16-89508421-G-A		Hereditary spastic paraplegia 7 • Hereditary spastic paraplegia • Inborn genetic diseases	Conflicting classifications of pathogenicity (Jan 18, 2024)
16-89508424-G-GTGC		Hereditary spastic paraplegia 7 • Hereditary spastic paraplegia	Uncertain significance (Jan 15, 2024)
16-89508424-G-GTGCTGCTGC		Hereditary spastic paraplegia 7	Uncertain significance (Jun 28, 2023)
16-89508426-G-A			Likely benign (Jul 30, 2018)
16-89508426-G-T		not specified • Hereditary spastic paraplegia 7 • Hereditary spastic paraplegia	Benign/Likely benign (Jan 31, 2024)
16-89508428-T-C		Hereditary spastic paraplegia 7	Uncertain significance (Nov 02, 2023)
16-89508430-C-T			Likely benign (Nov 01, 2016)
16-89508433-C-T		Hereditary spastic paraplegia 7	Likely benign (May 28, 2023)
16-89508436-C-A			Uncertain significance (Jul 01, 2019)
16-89508436-C-T		Hereditary spastic paraplegia 7	Likely benign (Aug 22, 2022)
16-89508435-G-GCTGCTC		Hereditary spastic paraplegia	Uncertain significance (Jun 01, 2018)
16-89508438-G-A		not specified	Likely benign (Mar 07, 2018)
16-89508442-C-T		Hereditary spastic paraplegia 7 • Inborn genetic diseases	Uncertain significance (Nov 07, 2022)
16-89508445-G-A		Hereditary spastic paraplegia 7	Uncertain significance (Apr 18, 2022)
16-89508445-G-T		Hereditary spastic paraplegia 7	Uncertain significance (Jun 08, 2022)
16-89508447-C-T		Hereditary spastic paraplegia 7	Likely benign (Jan 03, 2024)
16-89508449-T-C		Hereditary spastic paraplegia 7	Uncertain significance (Apr 02, 2019)

GnomAD

Source: gnomAD

Gene	Type	Bio Type	Transcript	Coding Exons	Length
SPG7	protein_coding	protein_coding	ENST00000268704	17	66852

pLI Probability LOF Intolerant	pRec Probability LOF Recessive	Individuals with no LOFs	Individuals with Homozygous LOFs	Individuals with Heterozygous LOFs	Defined	p
1.97e-36	8.36e-8	125322	2	424	125748	0.00170

	Z-Score	Observed	Expected	Observed/Expected	Mutation Rate	Total Possible in Transcript
Missense	-0.872	528	475	1.11	0.0000342	5129
Missense in Polyphen		205	215.61	0.95079		2137
Synonymous	-4.22	279	203	1.38	0.0000163	1632
Loss of Function	-1.69	48	36.9	1.30	0.00000225	416

LoF frequencies by population

Ethnicity	Sum of pLOFs	p
African & African-American	0.00212	0.00212
Ashkenazi Jewish	0.000497	0.000496
East Asian	0.000979	0.000979
Finnish	0.00107	0.00106
European (Non-Finnish)	0.00195	0.00191
Middle Eastern	0.000979	0.000979
South Asian	0.00357	0.00350
Other	0.00164	0.00163

dbNSFP

Source: dbNSFP

• Function: FUNCTION: ATP-dependent zinc metalloprotease. Plays a role in the formation and regulation of the mitochondrial permeability transition pore (mPTP) and its proteolytic activity is dispensable for this function (PubMed:26387735). {ECO:0000269|PubMed:26387735, ECO:0000305}.
• Disease: DISEASE: Spastic paraplegia 7, autosomal recessive (SPG7) [MIM:607259]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG7 is a complex form. Additional clinical features are cerebellar syndrome, supranuclear palsy, and cognitive impairment, particularly disturbance of attention and executive functions. {ECO:0000269|PubMed:16534102, ECO:0000269|PubMed:17646629, ECO:0000269|PubMed:20186691, ECO:0000269|PubMed:27217339, ECO:0000269|PubMed:9635427}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in SPG7 may cause autosomal recessive osteogenesis imperfecta (OI). Osteogenesis imperfecta defines a group of connective tissue disorders characterized by bone fragility and low bone mass. Clinical features of SPG7-related osteogenesis imperfecta include recurrent fractures, mild bone deformities, delayed tooth eruption, normal hearing and white sclera. {ECO:0000269|PubMed:20579626}.
• Pathway: Transport of small molecules;Mitochondrial calcium ion transport;Processing of SMDT1 (Consensus)

Intolerance Scores

• loftool: 0.103
• rvis_EVS: -1.05
• rvis_percentile_EVS: 7.62

Haploinsufficiency Scores

• pHI: 0.140
• hipred: N
• hipred_score: 0.294
• ghis: 0.624

Essentials

• essential_gene_CRISPR: N
• essential_gene_CRISPR2: N
• essential_gene_gene_trap: N
• gene_indispensability_pred: E
• gene_indispensability_score: 0.975

Gene Damage Prediction

	All	Recessive	Dominant
Mendelian	Medium	Medium	Medium
Primary Immunodeficiency	Medium	Medium	Medium
Cancer	Medium	Medium	Medium

Mouse Genome Informatics

• Gene name: Spg7
• Phenotype: growth/size/body region phenotype; skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan)

Gene ontology

• Biological process: proteolysis;mitochondrial calcium ion transmembrane transport;mitochondrion organization;nervous system development;anterograde axonal transport;regulation of mitochondrial membrane permeability;mitochondrial outer membrane permeabilization involved in programmed cell death
• Cellular component: mitochondrion;mitochondrial inner membrane;m-AAA complex;mitochondrial permeability transition pore complex;axon cytoplasm
• Molecular function: metalloendopeptidase activity;protein binding;ATP binding;peptidase activity;zinc ion binding;unfolded protein binding